Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fast And Furious: How The First-To-Market Advantage Is Shrinking

Executive Summary

The competitive dynamics in the pharmaceutical sector appear to be intensifying, with second- and third-to-market drugs reaching the market faster behind first-in-class drugs. That's putting more pressure on new drug launches and impacting drug pricing and rebating strategies.

You may also be interested in...



Novartis Allays Concerns Over Cosentyx Sales Miss

The Swiss major has calmed investor fears over the growth trajectory of Cosentyx, maintaining that its move into first-line therapy in ankylosing spondylitis and psoriatic arthritis, as well as psoriasis, will continue to drive sales.

AZ Looks To Lead Severe Asthma Market After US Fasenra OK

Following FDA approval, AstraZeneca believes that despite reaching the market after GlaxoSmithKline’s Nucala and Teva’s Cinqair, Fasenra's strong clinical package, convenient dosing and very competitive pricing will make it the leading biologic for severe asthma.

Q&A With US FDA Commissioner Scott Gottlieb

US FDA Commissioner Scott Gottlieb sat down with the Pink Sheet and Medtech Insight reporters for an exclusive chat about his ongoing regulatory work and plans for the future.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1132466

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel